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Dysfunctional ADAM22 implicated in
progressive encephalopathy with cortical
atrophy and epilepsy
ABSTRACT
Objective: To identify the molecular genetic basis of a syndrome characterized by rapidly pro-
gressing cerebral atrophy, intractable seizures, and intellectual disability.
Methods: We performed exome sequencing in the proband and whole-genome single nucleotide
polymorphism genotyping (copy number variant analysis) in the proband-parent trio. We used het-
erologous expression systems to study the functional consequences of identified mutations.
Results: The search for potentially deleterious recessive or de novo variants yielded compound
heterozygous missense (c.1202G.A, p.Cys401Tyr) and frameshift deletion (c.2396delG,
p.Ser799IlefsTer96) mutations in ADAM22, which encodes a postsynaptic receptor for LGI1.
The deleterious effect of the mutations was observed in cell surface binding and immunoprecip-
itation assays, which revealed that both mutant proteins failed to bind to LGI1. Furthermore,
immunoprecipitation assays showed that the frameshift mutant ADAM22 also did not bind to
the postsynaptic scaffolding protein PSD-95.
Conclusions: The mutations identified abolish the LGI1-ADAM22 ligand-receptor complex and are
thus a likely primary cause of the proband’s epilepsy syndrome, which is characterized by unusually
rapidly progressing cortical atrophy starting at 3–4 months of age. These findings are in line with the
implicated role of the LGI1-ADAM22 complex as a key player in nervous system development, spe-
cifically in functional maturation of postnatal synapses. Because the frameshift mutation affects an
alternatively spliced exon with highest expression in postnatal brain, the combined effect of the muta-
tions is likely to be hypomorphic rather than complete loss of function. This is compatible with the
longer survival of the patient compared to Lgi12/2 and Adam222/2mice, which develop lethal seizures
during the first postnatal weeks. Neurol Genet 2016;2:e46; doi: 10.1212/NXG.0000000000000046
GLOSSARY
ADLTE 5 autosomal dominant lateral temporal lobe epilepsy; cDNA 5 complementary DNA; CNV 5 copy number variant;
ER 5 endoplasmic reticulum; ExAC 5 Exome Aggregation Consortium; GFP 5 green fluorescent protein; OFC 5 occipital
frontal circumference; PNS 5 peripheral nervous system.
Many types of epilepsies are caused by genetic defects in ion channel or neurotransmitter genes,
but an alternative epileptogenic mechanism is revealed by dysfunction of the complexes formed
by the secreted neuronal glycoprotein LGI1 and its pre- and postsynaptic receptors ADAM23
and ADAM22, respectively.1,2 ADAM22 and ADAM23 are members of the ADAM
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(A Disintegrin And Metalloproteinase) family of
transmembrane proteins implicated in proteoly-
sis and cell adhesion.3 Unlike many ADAM pro-
teins, neuronally expressed ADAM22 and
ADAM23 are catalytically inactive and act by
binding to other proteins. LGI1-ADAM22 and
LGI1-ADAM23 complexes have recently been
suggested to function as transsynaptic players
forming macromolecular complexes regulating
synapse maturation and function, particularly
in postnatal brain1,2,4,5 (reviewed in reference
6). In addition to the postsynaptic membrane,
ADAM22 also functions in axons in the CNS7
and peripheral nervous system (PNS)8 and in
Schwann cells.8
LGI1, ADAM22, and ADAM23 are all
genetically linked to epilepsy. Heterozygous mu-
tations in LGI1, which impair LGI1 secretion or
binding to its receptors,9 cause autosomal dom-
inant lateral temporal lobe epilepsy (ADLTE;
OMIM #600512).10 Although ADAM22 and
ADAM23 mutations have not been reported in
human diseases, knockout mice for Lgi1,2,11,12
Adam22,13 and Adam2314 manifest with lethal
seizures during the first postnatal weeks. Further-
more, ADAM23 has been implicated in canine
epilepsy.15
Advances in high-throughput sequencing
methods have enhanced identification of genes
for rare disorders, including epilepsy syn-
dromes.16–18 We used whole-exome sequenc-
ing to characterize the genetic cause of a severe
infantile-onset progressive encephalopathy
with intractable seizures. We discovered com-
pound heterozygous mutations in ADAM22
that compromise the protein function.
METHODS Study patient. The proband was ascertained
from a series of 30 Finnish patients with severe epilepsy syn-
dromes who underwent whole-exome sequencing. The clinical
data were reviewed from hospital records. H.P. and M.S.
personally examined the patient. The original CT and MRI
images obtained prior to the age of 11 years were not available
for re-review.
Standard protocol approvals, registrations, and patient
consents. An institutional review board at the Helsinki Univer-
sity Hospital approved the study. Informed consent for DNA
analysis was obtained from the parents.
Exome sequencing and variant calling. Genomic DNA
extracted from peripheral blood of the proband was exome-
sequenced at the Wellcome Trust Sanger Institute (Hinxton,
Cambridge, United Kingdom) using methods described
previously.19 Briefly, SureSelect Human All Exon 50 Mb V3
RNA baits (Agilent Technologies, Santa Clara, CA) were used to
enrich exonic targets, and sequencing was carried out using HiSeq
2000 platform (Illumina, San Diego, CA). Alignment of the
sequence reads to Human Reference Genome hs37d5 (based on
GRCh37) and their further processing were performed as described
previously.19 Single nucleotide variants and indels of the proband
exome were called jointly with 84 previously published exomes19
and 42 unpublished in-house exomes using GATK
HaplotypeCaller (v. 3.3; https://www.broadinstitute.org/gatk/).20–22
Variant analysis under recessive and de novo inheritance
models. Reflecting the different possible inheritance patterns of
the underlying mutation(s) in the study patient with no affected
relatives, rare autosomal or sex-linked recessive and novel
heterozygous de novo mutations were explored. Mutations in
mitochondrial genome were also analyzed. The variant filtering
process is described in detail in appendix e-1 and figure e-1 at
Neurology.org/ng.
Variant validation and segregation analysis. Candidate var-
iants were confirmed, and segregation of the variants was analyzed
by bidirectional Sanger sequencing. Primers are available from the
authors upon request.
Analysis of copy number variants. Illumina Human CoreEx-
ome single nucleotide polymorphism array with 548K markers
enriched to genic regions was used to detect copy number variants
(CNVs) from genomic DNA isolated from peripheral blood of the
proband and parents and to confirm correct relatedness of DNA
samples in the proband-parent trio. PennCNV23 was used to call
CNVs (http://www.openbioinformatics.org/penncnv/).
Functional studies. Plasmid construction. The complemen-
tary DNA (cDNA) of human LGI1 was purchased from Thermo
Scientific (clone ID: 4811956) and subcloned into pCAGGS
with FLAG tag at its C-terminus. The cDNA of human
ADAM22 (same sequence as in NM_021723 except the
c.242C.G, p.Pro81Arg polymorphism in the Pro domain,
which is cleaved from the mature ADAM22) was subcloned into
pCAGGS. ADAM22 mutants Cys401Tyr and Ser799IlefsTer96
were generated by using site-directed mutagenesis. pGW1-PSD-
95-FLAG was constructed by replacing a green fluorescent pro-
tein (GFP) fragment of pGW1-PSD-95-GFP with a synthetic
DNA fragment encoding FLAG.24 All PCR products were veri-
fied by DNA sequencing.
Antibodies. The following antibodies were used: rabbit poly-
clonal antibodies to LGI1 (ab30868; Abcam, San Francisco, CA),
mouse monoclonal antibodies to KDEL (10C3; Enzo Life Scien-
ces, New York, NY), PSD-95 (MA1-046; Thermo Scientific,
Waltham, MA), and FLAG (M2; Sigma-Aldrich, St. Louis, MO).
Rabbit polyclonal antibodies to ADAM22 were raised against
GST-mouse ADAM22 (aa 444-526), corresponding to the
extracellular disintegrin domain. Antibodies were affinity-purified
on a cyanogen bromide–activated Sepharose 4B (GE Healthcare,
Piscataway, NJ) column containing the immunizing antigen.
Cell surface binding assay. The assay was performed in
COS7 cells with minor modifications to a previously reported
method.1 Details of the assay are presented in appendix e-1.
Immunoprecipitation. HEK293T cells were cotransfected
with wild-type LGI1-FLAG or PSD-95-FLAG together with
either wild-type ADAM22 or one of the ADAM22 mutants,
Cys401Tyr or Ser799IlefsTer96. The immune complexes were
precipitated with FLAG-M2 agarose and separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis. Gels were
subjected to Western blotting. A more detailed description of the
method is presented in appendix e-1.
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Accession codes. The raw aligned sequence reads were sub-
mitted to the European Genome-phenome Archive (https://
www.ebi.ac.uk/ega/home) by Wellcome Trust Sanger
Institute under study accession ID EGAS00001000190.
RESULTS Clinical features. The patient, currently 26
years of age, was born at term after an uncomplicated
pregnancy. She is the second child of healthy noncon-
sanguineous parents of Finnish ancestry, with no
family history of encephalopathy or epilepsy. During
pregnancy, fetal movements were normal. Birth
measurements were 3,700 g/51 cm (10.5 SD)/33.5
cm (21 SD). She had an Apgar score of 10 and was
discharged from the hospital normally. The first signs
of disease were brief episodes of apnea at 2 months of
age, and soon thereafter she lost her ability to smile
and make eye contact. At 3 months, she was hospi-
talized for repeated brief seizures. The seizures started
with focal symptoms and later generalized. EEG was
severely abnormal, and generalized spikes initiating
from the left side with abnormal background activity
were seen. The seizures proved to be intractable;
treatment with barbiturate anesthesia and phenobar-
bital, phenytoin, carbamazepine, and valproic acid in
different combinations was ineffective. The ammo-
nium levels were mildly and briefly elevated during
hospitalization, but metabolic screening tests re-
mained normal. At 3.5 and 4 months, the brain
CT was normal, but 6 weeks later, marked supraten-
torial atrophy was present. From 6 to 9 months the
seizures were better controlled, but thereafter she
started to have short focal clonic seizures or
myoclonias.
At 1 year of age, she was very hypotonic, with no
active movement, and had brisk reflexes in the lower
extremities and rigidity in both the upper and lower
extremities. She continued to have short tonic seizures,
sometimes with focal clonic jerks in her left eye and in
the corner of the mouth. The occipital frontal circum-
ference (OFC) was 43 cm (22.5 SD). She had a nar-
row forehead, open mouth, full lips, and a high and
narrow palate. The nose was short and the ear lobules
were outward-turning, and she had intermittent swell-
ing of extremities and face. Electroretinography was
normal. On brain MRI, the supratentorial atrophy
had progressed, and there was marked subdural effu-
sion. Cerebellum and brain stem were normal. In mor-
phologic assessment of muscle biopsy, nicotinamide
adenine dinucleotide and cytochrome c stainings were
normal, but frequent lipid vacuoles were seen. Electron
microscopic analysis of the sural nerve was normal, and
electroneuromyography also showed normal results.
The liver enzymes were moderately elevated, serum
lactate was slightly above normal range, and respiratory
chain analysis revealed unspecific changes (low con-
sumption of oxygen and high complex IV activity
with cytochrome c) not exclusively pointing toward
mitochondrial defect. Neuropathy, ataxia, retinitis
pigmentosa syndrome point mutation analysis and
mitochondrial DNA Southern blotting gave normal
results.
At 2 years, the OFC was 44.5 cm (23 SD) and
the CT showed marked supratentorial atrophy and
subdural effusion. The cerebellum was normal. She
experienced brief generalized seizures up to 4 times
per day and was treated with phenobarbital, valproic
acid, and diazepam. No voluntary movements were
seen, and microcephaly together with profound intel-
lectual disability was present. The ophthalmologic
examination was normal at 2 years and showed mild
atrophy of the optic nerve at 4 years 10 months. No
signs of hearing loss were noted, and sometimes an
auditory stimulus preceded a seizure. After the rapid
progression during the first year of life, her epilepsy
has remained stable with focal spikes and decreased
background activity. The MRI images at 11 years
showed severe cortical atrophy, widening of both
central and cortical CSF spaces, and skull thicken-
ing (figure 1). She is currently nonambulatory, has
intractable epilepsy, and is living in institutional
care.
Genetic analysis reveals compound heterozygous mutations
in ADAM22.We analyzed the exome variant data of the
proband (sequencing metrics in appendix e-1) for rare
and potentially deleterious autosomal or X-linked
Figure 1 Brain imaging findings in the patient
An axial T1-weighted MRI image of the patient at the age of
11 years. There is extensive loss of both gray and white
matter with corresponding widening of the CSF spaces
and thickening of the skull. Both thalami (arrows) show
shrinking and signal change.
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recessive mutations (figure e-1). Variants in 2 genes,
ADAM22 and CPA4, passed the recessive filtering
(figure e-1, table e-1), but only the mutations in
ADAM22 segregated in an autosomal recessive manner
in the family (figure 2A and figure e-2). The patient
was compound heterozygous for a missense mutation
c.1202G.A encoding the p.Cys401Tyr substitution
(mutation nomenclature based on ADAM22 variant
1, RefSeq ID NM_021723) and a 1-bp frameshift
deletion c.2396delG (p.Ser799IlefsTer96). The
missense mutation is present in the heterozygous
state in 2 individuals of European ancestry in the
Exome Aggregation Consortium (ExAC) database
(http://exac.broadinstitute.org/), yielding an allele
frequency of 1.658 3 1025. The deletion mutation
is novel. The missense substitution, p.Cys401Tyr,
occurs in a highly conserved cysteine residue that
forms a disulfide bond with Cys394 in the
metalloproteinase domain25 (figure 2, B and C and
figure e-3). The p.Cys401Tyr substitution is
predicted to be deleterious by all 4 in silico
methods used. The frameshift deletion is predicted
to alter the last ;100 residues of ADAM22, thus
abolishing the PDZ-binding motif (figure 2B). The
deletion occurs in exon 27 of the longest isoform of
ADAM22 (RefSeq ID NM_021723), which encodes
Figure 2 Compound heterozygous mutations in ADAM22
(A) Segregation of the mutations in the family. Arrow indicates the exome-sequenced patient.1, wild-type. (B) Domain structure of ADAM22 and location of
the mutations. Exon numbering and mutation positions are based on the longest isoform of ADAM22 (variant 1, NM_021723). (C) ClustalX (http://www.
clustal.org/clustal2/) comparison of amino acid sequences surrounding Cys401 shows full conservation of Cys401 (arrow) across different vertebrate
species. Fully conserved, strongly similar, and weakly similar amino acid residues are labeled with asterisks, colon, and periods, respectively.
4 Neurology: Genetics
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
residues in the cytoplasmic tail and is subjected to
alternative splicing26,27 (figures e-4 and e-5, see also
Discussion).
Eight variants passed the filtering under the “de
novo” hypothesis, where we looked for novel hetero-
zygous variants (figure e-1, table e-1). Because the
parents were not exome- sequenced, we analyzed seg-
regation of these variants by capillary sequencing. All
8 variants were inherited from an unaffected parent
and thus were not considered pathogenic. Variants in
mitochondrial DNA were known polymorphisms
(data not shown).
Analysis of CNVs in the proband-parent trio did
not yield likely pathogenic variants (data not shown).
ADAM22 mutants show aberrant binding to LGI1.
Using a cell surface binding assay, we first examined
whether LGI1 interacts with the ADAM22 mutants.
When LGI1 was cotransfected with wild-type
ADAM22, LGI1 efficiently bound to ADAM22 on
the cell surface as previously reported1 (figure 3A).
In contrast, LGI1 did not bind to the Cys401Tyr
and Ser799IlefsTer96 mutants on the cell surface.
Although the localization of the Cys401Tyr mutant
was similar to that of the wild type, most of the
Ser799IlefsTer96 mutant protein was localized in
the endoplasmic reticulum (ER), labeled by anti-
KDEL antibody (figure 3, A and B).
We next analyzed the heterologous expression of
ADAM22mutants in HEK293T cells by Western blot-
ting. The expression level of Cys401Tyr was comparable
to that of the wild type, whereas Ser799IlefsTer96 was
less expressed in HEK293T cells and remained as an
immature form (propeptide not cleaved, see inputs in
figure 3, C and D). When LGI1 was cotransfected with
wild-type ADAM22, ADAM22was efficiently coimmu-
noprecipitated with LGI1 (figure 3C). In contrast, nei-
ther the Cys401Tyr nor the Ser799IlefsTer96 mutant
was coimmunoprecipitated with LGI1 (figure 3C,
arrowheads). We also found that the wild-type
ADAM22 and Cys401Tyr mutant, which have a
PDZ-binding motif at their C-terminus, bound to
the postsynaptic scaffolding protein PSD-95, as shown
previously for wild-type ADAM22,1 but Ser799Ilef-
sTer96 lacking the motif did not (figure 3D).
Figure 3 ADAM22 mutant proteins do not bind to LGI1
(A) Fluorescent confocal microscope images from the cell surface binding assay, in which
indicated ADAM22 complementary DNAs were cotransfected with wild-type FLAG-tagged
LGI1 into COS7 cells. Surface-bound FLAG-tagged LGI1 was labeled before cell permeabi-
lization (red) and then ADAM22 was stained (green). Both ADAM22 mutants fail to bind to
LGI1. Bar: 20 mm. (B) Ser799IlefsTer96 mutant (green) is localized in the endoplasmic retic-
ulum labeled by the anti-KDEL antibody (red). Regions outlined with white squares are
magnified in the upper right of the images. Bar: 20 mm. (C,
D) Immunoprecipitation of ADAM22 mutants with FLAG-
tagged LGI1 (C) or PSD-95 (D) in HEK293T cells. Neither
ADAM22 mutant binds to LGI1 (left panel in C). The
Cys401Tyr mutant binds to PSD-95, but the Ser799Ilef-
sTer96 mutant does not (left panel in D). Arrows and arrow-
heads indicate the positions of immature and mature
ADAM22, respectively. Immature ADAM22 is often
observed in overexpressed cells and seems to nonspecifi-
cally bind to LGI1 under these conditions, whereas in the
brain the immature band is not observed.
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DISCUSSION We identified compound heterozygous
loss-of-function mutations in ADAM22 in a patient
with rapidly progressing severe encephalopathy
with intractable seizures and profound intellectual
disability. After initially normal CT scans, a
remarkable feature of her disease was the rapidly
progressing cerebral atrophy (within only a few
weeks) with subdural effusions that became apparent
approximately 2 months after seizure onset. The brain
imaging changes were very similar to those seen in
Menkes syndrome,28,29 and the patient’s symptoms
also resemble those seen in Alpers syndrome.30 The
disease course of the patient was also unusual. The
progression was very rapid in infancy after the onset
of intractable seizures at 3 months of age, following the
apparently normal first months of life. Thereafter
the condition stabilized, leaving the patient
nonambulatory with intractable seizures, and she is
still alive at the age of 26 years. A rapidly progressing
disease course in infancy may be a characteristic feature
for ADAM22-associated disease, related to the role of
ADAM22 in postnatal brain development.
We searched for pathogenic recessive and de novo
variants in the exome and CNV data. The only variants
passing the filtering and having a compatible segregation
pattern in the family were compound heterozygous mu-
tations in ADAM22 (figure e-1). The ability to dramat-
ically reduce the number of candidate variants when
only the proband was exome-sequenced was possible
by filtering against comprehensive variant databases
including population-matched individuals, in our case
Finns in the ExAC database.
Our functional assays indicated that both mutations
cause a nonfunctional ADAM22 protein. The Cys401-
Tyr mutant did not bind to LGI1 in cell surface binding
and immunoprecipitation assays. The p.Cys401Tyr
substitution is predicted to break a disulfide bond in
the metalloproteinase-like (M) domain. The crystal
structure of the extracellular domain of ADAM22 has
been recently determined25 (figure e-3). Based on this
structure, the authors suggested a modular movement
model of ligand binding to ADAM22, where the ligand,
LGI1, competes with theM domain in binding with the
cysteine-rich domain (C), making the M domain move
away from the C domain.25 Because the p.Cys401Tyr
substitution likely affects the tertiary structure of the M
domain, it may hinder the conformational change that is
necessary for ADAM22 in implementing its protein–
protein adhesion function.
Because the C-terminal PDZ-binding motif is
intact in the Cys401Tyr mutant, its binding to PSD-
95 appeared normal in the immunoprecipitation assay.
On the contrary, the frameshift mutation is predicted
to alter the ;100 amino acids in the cytoplasmic part
of the protein, including residues binding to cytoplas-
mic PSD-95 (figure 2B) and 14-3-3 proteins.1,5,31 Our
binding assays showed that the frameshift mutation
leads to a nonfunctional protein that is localized mainly
in the ER and does not bind to LGI1 or to PSD-95.
The highly conserved exon 27 containing the
frameshift deletion is subjected to alternative splicing
(figure e-4), as are several other exons encoding parts
of the cytoplasmic domain of ADAM22. Exon 27 is
expressed in several regions of the human and mouse
brain13,26,27,32 and has a progressive temporal expres-
sion pattern that differs from that of ADAM22
exons that are not subjected to alternative splicing
(figure e-5).33 Accounting for all exons, ADAM22
expression is highest in postnatal stages (reference
1 and figure e-5). In embryonic stages, exon 27 is
expressed in lower levels than other exons; the pro-
portion of splice variants expressing exon 27 rapidly
increases toward the end of the embryonic develop-
ment and reaches a plateau at the first postnatal
months. Exon 27 does not contain known peptide
motifs, but its temporal expression pattern suggests that
it contains residues playing a role in the CNS function
in postnatal stages in particular. Reflecting the impor-
tance of LGI1–ADAM22/23 complexes in postnatal
brain development, the Lgi12/2, Adam222/2, and
Adam232/2 mice start developing seizures around
10 postnatal days.2,11–14 The expression pattern of
ADAM22 and data from knockout mice are in line
with the development of symptoms in our patient,
who was apparently asymptomatic at birth, with the
first symptoms appearing at approximately 2 months of
age and the disease progressing rapidly thereafter.
Because not all ADAM22 transcripts express exon
27, the frameshift mutation is likely not a total null
mutation but rather a hypomorphic one, its effect
increasing temporally. This may also explain why
the compound heterozygous mutations in our patient
were not lethal in early life, in contrast to Lgi12/2,
Adam222/2, and Adam232/2 mice, which die at 2–3
postnatal weeks.2,11–14 Furthermore, exon 27 is skip-
ped from ADAM22 in the PNS,8,13,32 which may
explain why sural biopsy shows normally myelinated
nerves in the proband, whereas the knockout mice
present with marked hypomyelination of the periph-
eral nerves.13
One epileptogenic mechanism of LGI1–
ADAM22 dysfunction could stem from the observa-
tions that loss of neuronal LGI1 reduces AMPAR-
mediated synaptic transmission1,2 and that loss of
ADAM22 reduces both AMPAR- and NMDAR-
mediated currents in excitatory synapses.5 This role
of the LGI1-ADAM22 complex as the regulator of
functional maturation of excitatory synapses in post-
natal stages is mediated by interaction between the
PDZ-binding motif of ADAM22 and PSD-95.5
When the complex is dysfunctional, it leaves synapses
immature5 and could promote seizure activity, as has
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been shown for a monoallelic LGI1 mutant.4 Reduc-
tion of synaptic AMPARs as a consequence of the
disruption of LGI1-ADAM22 interaction has also
been suggested34 to be the underlying epileptogenic
pathomechanism in autoimmune limbic encephali-
tis, which manifests with amnesia and seizures and is
caused by autoantibodies against LGI1.35,36 It re-
mains unknown whether seizure activity contributes
to the rapidly progressive degeneration of cortical
regions in our patient or whether ADAM22 dys-
function has a direct negative effect on the develop-
ment of neuronal connections, increasing seizure
susceptibility.
Our data suggest that loss of ADAM22 function
in the CNS underlies the severe rapidly progressing
infantile-onset encephalopathy with epilepsy in our
patient. Given that heterozygous LGI1 mutations
underlie ADLTE, previous studies have attempted
to identify dominantly inherited mutations in
ADAM22 in ADLTE families.37,38 However, the fact
that the parents of the proband—who are heterozy-
gous carriers of loss-of-function mutations—do not
have epilepsy indicates that heterozygous deleterious
mutations are tolerated in ADAM22 and that
ADAM22 is primarily a recessive disease gene. This
hypothesis is supported by the presence of 9 truncat-
ing variants of the canonical ADAM22 transcript in
the ExAC database, whereas there are none for LGI1.
Lack of rare biallelic mutations in ADAM22 in
other exome data sets (appendix e-1) indicates that
ADAM22-associated encephalopathy is rare, which
may partially be because complete knockout muta-
tions of ADAM22 are not tolerated and only hypo-
morphic mutations cause a phenotype similar to that
in our study. Future studies are needed to confirm
this genetic association and define the phenotypic
presentations of ADAM22 dysfunction.
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